Advertisement

Volume 132, Issue 15

 

 

October 11, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: TAFI drives joint bleeding in congenital hemophilia A. See the article by Wyseure et al.

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
This study shows that the combination of three novel agents approved for chronic lymphocytic leukemia (ibrutinib, venetoclax, and obinutuzumab) can be safely combined at standard doses to create an active, chemotherapy-free triplet regimen for relapsed or refractory disease.


Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding
The investigators demonstrate that defective activation of thrombin-activatable fibrinolysis inhibitor (TAFI) drives joint bleeding in congenital, but not acquired, hemophilia A.


Chronic immune response dysregulation in MDS pathogenesis
This Blood Spotlight discusses the current understanding of innate immune dysregulation and inflammatory pathways in the pathogenesis of myelodysplastic syndromes (MDSs).


Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks
The authors review advances in the diagnosis and therapeutic management of intravascular diffuse large B-cell lymphoma.


Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group
Childhood acute myeloid leukemia (AML) is highly heterogeneous. In this study, the investigators identified 2 distinct pediatric t(16;21) AML subgroups that exhibit unique molecular and prognostic features. Evidence suggests that these patients require distinct treatments.


Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse
Using posttransplant next-generation sequencing for posttransplant monitoring in patients with AML patients, the investigators identified patients with a high risk of relapse and mortality.


Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use
This novel mouse model whereby murine Mcl-1 has been exchanged for human MCL-1 recapitulates the biological function of murine Mcl-1 and allows therapeutic testing of Mcl-1 inhibitors.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.